title: [Results of a multidisciplinary program to quit smoking].
abstract: BACKGROUND
  Therapies to quit smoking are based on counseling, psychological therapy (PT), nicotine replacement therapy, bupropion or varenidine.
  
  
  OBJECTIVE
  To report the results of a multidisciplinary program to quit smoking.
  
  
  METHODS
  Patients aged l8 years or more, motivated to quit smoking were admitted in a program based in counseling and PT, with or without pharmacological therapy. They were assessed by telephone during one year of follow up. Patients with unstable psychiatric diseases were excluded. Results were considered as "successful" when patients maintained abstinence during the year of follow up. A logistic regression analysis was done to identify factors associated with treatment success.
  
  
  RESULTS
  Between 2005 and 2011, 198 patients aged 45 ± 11 years (56% males), who smoked 31.5 ± 20.6 packages/year, were treated. Of these, 155 (78%) were treated with varenidine, 26 (13%) with bupropion and 17 (9%>) did not receive pharmacological therapy. One hundred sixty eight patients completed the year of follow up. In 82 (49%>), treatment was successful and was negatively associated with a history of depression (odds ratio = 4 (95% confidence intervals 1.23-38.33). The main side effeets associated to varenidine and bupropion were nausea in 37 and 23%o, sleep disorders in 20 and 19%o and headache in 12 and 0%>, respectively.
  
  
  CONCLUSIONS
  A multidisciplinary program to quit smoking achieved a 49%> of abstinence during a year of follow up.
authors.affiliation: Departamento de Enfermedades Respiratorias, Clínica Santa María, Santiago, Chile. ppena@csm.cl
authors.forename: Pedro
authors.initials: P
authors.lastname: Peña
authors.forename: Mónica
authors.initials: M
authors.lastname: Zagolin
authors.forename: Mónica
authors.initials: M
authors.lastname: Acuña
authors.forename: Sandra
authors.initials: S
authors.lastname: Navarrete
authors.forename: Pilar
authors.initials: P
authors.lastname: Bustamante
authors.forename: Claudio
authors.initials: C
authors.lastname: Suárez
authors.forename: Gabriel
authors.initials: G
authors.lastname: Cavada
authors.forename: M Paz
authors.initials: MP
authors.lastname: Bertoglia
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D016642:Bupropion / Q000009:adverse effects / Q000627:therapeutic use*; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy / Q000379:methods; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018722:Nicotinic Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D010348:Patient Care Team; D015397:Program Evaluation; D011810:Quinoxalines / Q000009:adverse effects / Q000627:therapeutic use*; D012907:Smoking / Q000628:therapy*; D016540:Smoking Cessation / Q000379:methods*; D012959:Socioeconomic Factors; D016896:Treatment Outcome; D000068580:Varenicline; D055815:Young Adult
chemical_list: D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D000068580:Varenicline